AccScience Publishing / AN / Volume 1 / Issue 1 / DOI: 10.36922/an.v1i1.2
Cite this article
280
Download
2297
Views
Journal Browser
Volume | Year
Issue
Search
News and Announcements
View All
SPECIAL FEATURE ARTICLE

Insights on amyloid-related imaging abnormalities from the “Pre-Alzheimer’s disease Alliance of China”

Tao-Ran Li1 Ying Han1,2,3,4* on behalf of the Pre-AD Alliance of China5
Show Less
1 Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, 100053, China
2 School of Biomedical Engineering, Hainan University, Haikou, 570228, China
3 Center of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing, 100053, China
4 National Clinical Research Center for Geriatric Diseases, Beijing, 100053, China
5 Pre-AD Alliance of China, http://www.alzheimer.org.cn/
Advanced Neurology 2022, 1(1), 2 https://doi.org/10.36922/an.v1i1.2
Submitted: 29 November 2021 | Accepted: 25 February 2022 | Published: 18 March 2022
© 2022 by the Authors. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Abstract

Alzheimer’s disease (AD) is the most common cause of dementia and accounts for 60 – 80% of all such cases. For approximately 20 years, the research and development of new drugs for AD all ended in failure; however, aducanumab was recently granted accelerated approval by the US Food and Drug Administration. Aducanumab is a representative passive anti-β-amyloid (Aβ) immunotherapy and is the only approved drug that directly targets the pathological changes of AD; it can significantly reduce brain Aβ deposition, which is a hallmark of AD. During the clinical trials of amyloid-targeting monoclonal antibodies, represented by aducanumab, amyloid-related imaging abnormalities (ARIA) were the most common and important adverse reactions. Therefore, before the large-scale clinical application of amyloid-targeting monoclonal antibodies, clinicians and radiologists need to fully understand ARIA so that they can make more informed decisions. Considering the very uneven distribution of medical resources in China, we — on behalf of the “Pre-AD Alliance of China” — believe that it is necessary to write a consensus to elaborate on the mechanisms, risk factors, identification methods, and administration processes of ARIA.

Keywords
Alzheimer’s disease
Amyloid-related imaging abnormalities
Edema
Sulcal effusion
Microhemorrhage
Superficial siderosis
Funding
National Natural Science Foundation of China
References
[1]

Gauthier S, Rosa-Neto P, Morais JA, et al., 2021, World Alzheimer Report 2021: Journey Through the Diagnosis of Dementia. Alzheimer’s Disease International, England.

[2]

Collaborators GD, 2019, Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990- 2016: A systematic analysis for the global burden of disease study 2016. Lancet Neurol, 18(1): 88–106.

[3]

Drew L, 2018, An age-old story of dementia. Nature, 559(7715): S2–S3.

[4]

Wu YT, Beiser AS, Breteler MM, et al., 2017, The changing prevalence and incidence of dementia over time-current evidence. Nat Rev Neurol, 13(6): 327–339.

[5]

Jia L, Du Y, Chu L, et al., 2020, Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: A cross-sectional study. Lancet Public Health, 5(12): e661–e671.

[6]

Jia J, Wei C, Chen S, et al., 2018, The cost of Alzheimer’s disease in China and re-estimation of costs worldwide. Alzheimers Dement, 14(4): 483–491.

[7]

Jia L, Quan M, Fu Y, et al., 2020, Dementia in China: Epidemiology, clinical management, and research advances. Lancet Neurol, 19(1): 81–92. http://doi.org/10.1016/S1474-4422(19)30290-X

[8]

Scheltens P, De Strooper B, Kivipelto M, et al., 2021, Alzheimer’s disease. Lancet, 397(10284): 1577–1590. http://doi.org/10.1016/S0140-6736(20)32205-4

[9]

Long JM, Holtzman DM, 2019, Alzheimer disease: An update on pathobiology and treatment strategies. Cell, 179(2): 312–339. http://doi.org/10.1016/j.cell.2019.09.001

[10]

Jan AT, Azam M, Rahman S, et al., 2017, Perspective insights into disease progression, diagnostics, and therapeutic approaches in Alzheimer’s disease: A judicious update. Front Aging Neurosci, 9: 356. http://doi.org/10.3389/fnagi.2017.00356

[11]

Luo J, Agboola F, Grant E, et al., 2020, Sequence of Alzheimer disease biomarker changes in cognitively normal adults: A cross-sectional study. Neurology, 95(23): e3104-e3116. http://doi.org/10.1212/WNL.0000000000010747

[12]

Palmqvist S, Insel PS, Stomrud E, et al., 2019, Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer’s disease. EMBO Mol Med, 11(12): e11170.

[13]

Guo T, Korman D, Baker SL, et al., 2021, Longitudinal cognitive and biomarker measurements support a unidirectional pathway in Alzheimer’s disease pathophysiology. Biol Psychiatry, 89(8): 786–794. http://doi.org/10.1016/j.biopsych.2020.06.029

[14]

Jack CJ Jr., Wiste HJ, Therneau TM, et al., 2019, Associations of amyloid, tau, and neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia. JAMA, 321(23): 2316–2325.

[15]

Jack CR Jr., Bennett DA, Blennow K, et al., 2018, NIA-AA research framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement, 14(4): 535–562. http://doi.org/10.1016/j.jalz.2018.02.018

[16]

Donohue MC, Sperling RA, Petersen R, et al., 2017, Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. JAMA, 317(22): 2305–2316. http://doi.org/10.1001/jama.2017.6669

[17]

Cummings J, Lee G, Zhong K, et al., 2021, Alzheimer’s disease drug development pipeline: 2021. Alzheimers Dement (NY), 7(1): e12179. http://doi.org/10.1002/trc2.12179

[18]

Cummings J, Aisen P, Lemere C, et al., 2021, Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. Alzheimers Res Ther, 13(1): 98. http://doi.org/10.1186/s13195-021-00838-z

[19]

Salloway S, Sperling R, Gilman S, et al., 2009, A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology, 73(24): 2061– 2070.

[20]

Jeremic D, Jiménez-Díaz L, Navarro-López JD, 2021, Past, present and future of therapeutic strategies against amyloid- beta peptides in Alzheimer’s disease: A systematic review. Ageing Res Rev, 72: 101496. http://doi.org/10.1016/j.arr.2021.101496

[21]

DiFrancesco JC, Longoni M, Piazza F, 2015, Anti-abeta autoantibodies in amyloid related imaging abnormalities (ARIA): Candidate biomarker for immunotherapy in Alzheimer’s disease and cerebral amyloid angiopathy. Front Neurol, 6: 207. http://doi.org/10.3389/fneur.2015.00207

[22]

Sperling RA, Jack CR Jr., Black SE, et al., 2011, Amyloid- related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s association research roundtable workgroup. Alzheimers Dement, 7(4): 367–385. http://doi.org/10.1016/j.jalz.2011.05.2351

[23]

Barakos J, Sperling R, Salloway S, et al., 2013, MR imaging features of amyloid-related imaging abnormalities. AJNR Am J Neuroradiol, 34(10): 1958–1965.

[24]

Cummings J, Aisen P, Apostolova LG, et al., 2021, Aducanumab: Appropriate use recommendations. J Prev Alzheimers Dis, 8(4): 398–410.

[25]

Haeberlein SB, von Hehn C, Tian Y, et al., 2019, EMERGE and ENGAGE Topline Results: Two Phase 3 Studies to Evaluate Aducanumab in Patients With Early Alzheimer’s Disease. Available from: https://investors.biogen.com/ static-files/f91e95d9-2fce-46ce-9115-0628cfe96e83 [Last accessed on 2022 Mar 16].

[26]

Sperling R, Salloway S, Brooks DJ, et al., 2012, Amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with bapineuzumab: A retrospective analysis. Lancet Neurol, 11(3): 241–249. http://doi.org/10.1016/S1474-4422(12)70015-7

[27]

Carlson C, Estergard W, Oh J, et al., 2011, Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer’s disease study cohorts from phase 3 trials of semagacestat and solanezumab. Alzheimers Dement, 7(4): 396–401. http://doi.org/10.1016/j.jalz.2011.05.2353

[28]

Pichler M, Vemuri P, Rabinstein AA, et al., 2017, Prevalence and natural history of superficial siderosis: A population based study. Stroke, 48(12): 3210–3214. http://doi.org/10.1161/STROKEAHA.117.018974

[29]

Vernooij MW, van der Lugt A, Ikram MA, et al., 2008, Prevalence and risk factors of cerebral microbleeds: The Rotterdam scan study. Neurology, 70(14): 1208–1214. http://doi.org/10.1212/01.wnl.0000307750.41970.d9

[30]

Gutt S, Brocco A, Sharma S, 2019, Variability of Aria Detection in Patients Receiving Monoclonal Antibodies Against Amyloid-β PLAQUES, Poster Presented at AAIC 2019 (P1-045).

[31]

Avgerinos KI, Ferrucci L, Kapogiannis D, 2021, Effects of monoclonal antibodies against amyloid-beta on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer’s disease. Ageing Res Rev, 68: 101339. http://doi.org/10.1016/j.arr.2021.101339

[32]

Ketter N, Brashear HR, Bogert J, et al., 2017, Central review of amyloid-related imaging abnormalities in two Phase III clinical trials of bapineuzumab in mild-to-moderate Alzheimer’s disease patients. J Alzheimers Dis, 57(2): 557–573. http://doi.org/10.3233/JAD-160216

[33]

Brashear HR, Ketter N, Bogert J, et al., 2018, Clinical evaluation of amyloid-related imaging abnormalities in bapineuzumab phase III studies. J Alzheimers Dis, 66(4): 1409–1424. http://doi.org/10.3233/JAD-180675

[34]

Ostrowitzki S, Lasser RA, Dorflinger E, et al., 2017, A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease. Alzheimers Res Ther, 9(1): 95. http://doi.org/10.1186/s13195-017-0318-y

[35]

Swanson CJ, Zhang Y, Dhadda S, et al., 2021, A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Abeta protofibril antibody. Alzheimers Res Ther, 13(1): 80. http://doi.org/10.1186/s13195-021-00813-8

[36]

Arrighi HM, Barakos J, Barkhof F, et al., 2016, Amyloid- related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer’s disease treated with bapineuzumab: A historical, prospective secondary analysis. J Neurol Neurosurg Psychiatry, 87(1): 106–112. http://doi.org/10.1136/jnnp-2014-309493

[37]

Chalkias S, Umans K, Castrillo-Viguera C, et al., 2021, Considerations for the Real-World Management of ARIA From the Aducanumab Phase 3 Studies EMERGE and ENGAGE. AAIC 2021 Poster 57498.

[38]

Liu E, Wang D, Sperling R, et al., 2018, Biomarker Pattern of ARIA-E Participants in Phase 3 Randomized Clinical Trials with Bapineuzumab. Neurology, 90(10): e877–e886.

[39]

Budd HS, O’Gorman J, Chiao P, et al., 2017, Clinical development of aducanumab, an anti-abeta human monoclonal antibody being investigated for the treatment of early Alzheimer’s disease. J Prev Alzheimers Dis, 4(4): 255–263. http://doi.org/10.14283/jpad.2017.39

[40]

Salloway S, Sperling R, Fox NC, et al., 2014, Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med, 370(4): 322–333. http://doi.org/10.1056/NEJMoa1304839

[41]

Zago W, Schroeter S, Guido T, et al., 2013, Vascular alterations in PDAPP mice after anti-Abeta immunotherapy: Implications for amyloid-related imaging abnormalities. Alzheimers Dement, 9 Suppl 5: S105–S115. http://doi.org/10.1016/j.jalz.2012.11.010 

[42]

Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, et al., 2020, Cerebral amyloid angiopathy and Alzheimer disease- one peptide, two pathways. Nat Rev Neurol, 16(1): 30–42. http://doi.org/10.1038/s41582-019-0281-2

[43]

Caselli RJ, Walker D, Sue L, et al., 2010, Amyloid load in nondemented brains correlates with APOE e4. Neurosci Lett., 473(3): 168–171. http://doi.org/10.1016/j.neulet.2010.02.016

[44]

Harrison CH, Sakai K, Johnston DA et al., 2019, The Role of Capillary Angiopathy and Aquaporin 4 in Aria Induced by Aβ Immunization, Oral Presentation at AAIC 2019 (O3- 10-03).

[45]

Blockx I, Einstein S, Guns PJ, et al., 2016, Monitoring blood-brain barrier integrity following amyloid-beta immunotherapy using gadolinium-enhanced MRI in a PDAPP mouse model. J Alzheimers Dis, 54(2): 723–735. http://doi.org/10.3233/JAD-160023 

[46]

Eng JA, Frosch MP, Choi K, et al., 2004, Clinical manifestations of cerebral amyloid angiopathy-related inflammation. Ann Neurol, 55(2): 250–256. http://doi.org/10.1002/ana.10810

[47]

Kinnecom C, Lev MH, Wendell L, et al., 2007, Course of cerebral amyloid angiopathy-related inflammation. Neurology, 68(17): 1411–1416. http://doi.org/10.1212/01.wnl.0000260066.98681.2e

[48]

Piazza F, Greenberg SM, Savoiardo M, et al., 2013, Anti- amyloid beta autoantibodies in cerebral amyloid angiopathy- related inflammation: Implications for amyloid-modifying therapies. Ann Neurol, 73(4): 449–458. http://doi.org/10.1002/ana.23857

[49]

Administration, US, FDA. Drugs@FDA: FDA Approved Drugs. Aducanumab; 2021. Available from: https://www. fda.gov/drugs/news-events-human-drugs/fdas-decision-approve-new-treatment-alzheimers-disease [Last accessed on 2022 Mar 16].

[50]

Mullard A, 2021, Landmark Alzheimer’s drug approval confounds research community. Nature, 594(7863): 309–310. http://doi.org/10.1038/d41586-021-01546-2 

[51]

Steinbrook R, 2021, The accelerated approval of aducanumab for treatment of patients with Alzheimer disease. JAMA Intern Med, 181(10): 1281. http://doi.org/10.1001/jamainternmed.2021.4622

[52]

Planche V, Villain N, 2021, US food and drug administration approval of aducanumab-is amyloid load a valid surrogate end point for Alzheimer disease clinical trials? JAMA Neurol, 78(11): 1307–1308. http://doi.org/10.1001/jamaneurol.2021.3126

Conflict of interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Share
Back to top
Advanced Neurology, Electronic ISSN: 2810-9619 Published by AccScience Publishing